With the growing integration of non–vitamin K antagonist oral anticoagulants (NOACs) into
clinical practice, questions have arisen regarding their use in special populations, including …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

ABSTRACT Introduction: Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) are at
least as effective as vitamin K antagonists (VKAs) reducing thromboembolism and mortality …

Background: New oral anticoagulant agents (NOACs) are valid alternatives for vitamin K
antagonists (VKA) in patients with non-valvular atrial fibrillation (NVAF) for stroke prevention …

Introduction Hypertension is associated with increased risk of stroke and bleeding in
patients with atrial fibrillation (AF). In the present study, we aimed to investigate the influence …

Atrial fibrillation (AF) is the most prevalent arrhythmia and is associated with an increased
risk of ischemic stroke (IS) and systemic embolism (SE). Stroke prevention is a key element …

Introduction Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for
stroke prevention in patients with atrial fibrillation (AF). Since NOACs are predominantly …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …

Background The reversibility of new/novel oral anticoagulants (NOAC) is not well
understood, whereas the reversal strategies for bleeding associated with vitamin k …